Kix360° Vitals combines Nonagon’s N9+ remote examination device with round-the-clock pediatric virtual care, but affordability, caregiver technique and clinical escalation will determine whether it genuinely reduces unnecessary hospital visits.
See how VeriSIM Life’s FDA/NCTR research collaboration could shape transparent mechanistic AI for safer, faster drug development.
Discover how Undue Medical Debt’s $550 million California relief reshapes healthcare affordability while exposing deeper billing risks.
See how MedX Health’s SkinSecure could reshape collagen endpoints in skin trials and which validation risks researchers must watch.
CalciMedica has preserved the clinical future of Auxora after regulators reviewed safety data from the KOURAGE trial, but restarting development is only the beginning of a difficult scientific and financial recovery.
Quest Diagnostics has taken Haystack MRD nationwide after New York approval. See how ctDNA testing could reshape cancer recurrence monitoring.
Nano-X Imaging increased first-quarter revenue and placed its Nanox.ARC at a RadNet site, but slow activations, withdrawn guidance and a going-concern warning leave the medical imaging company facing a difficult commercial test.
NRx’s HOPE Therapeutics begins Zeta-guided TMS treatments, bringing AI-powered image guidance into outpatient depression care workflows.
CalciMedica can continue developing Auxora after the FDA reviewed KOURAGE safety data without imposing a clinical hold, but a large financing, major potential dilution and a strategic shift toward pulmonary hypertension redefine the CALC investment case.
CONNEQT Health is seeking an FDA pathway for cloud-based arterial analytics, but regulatory execution, customer integration, cash burn and a heavily dilutive capital raise complicate the ASX micro-cap opportunity.